The main result was for the combination
CagriSema pairs cagrilintide with semaglutide (Ozempic, Wegovy).
The study called REDEFINE 1 followed 3,417 adults with excess weight and without diabetes for 68 weeks.
- The main calculation counted everyone who started, including people who later stopped treatment.
- On that basis, average weight loss was 20.4% with CagriSema and 3.0% with dummy shots.
- The developer also reported a calculation of what might happen if everyone stayed on treatment.
- That calculation gave 22.7% average weight loss with CagriSema and 2.3% with dummy shots.
- It used the same study, with a different assumption about staying on treatment.
- Participants attended regular visits and received advice on food and physical activity.
- Novo Nordisk, the drug’s developer, funded the study.
Cagrilintide alone had a different result
For cagrilintide alone, the developer reported 11.5% average weight loss in the same study. This calculation counted everyone who started.
- The cagrilintide-alone group was smaller. The study’s main comparison was CagriSema against dummy shots.
- The 11.5% figure came from the company’s announcement, not the journal paper’s summary. Keep that limit with the number.
- A result for the combination cannot be used to describe a solo product.
- These were trial averages, with results differing from person to person.
Ask what the headline leaves out
Keep the result beside the question it answered.
- Which people could join?
- How long were they followed?
- What care came with the drug?
- What problems occurred?
- Did the figure come from a journal paper or a company announcement?